A global remdesivir clinical trial came to Iowa via the University of Iowa Hospital & Clinics in the ongoing effort to take on COVID-19. The hospital is one of 70 sites worldwide doing a clinical trial. All of the sites combined, a total of 1,600 targeted patients in a study of moderate disease severity and 2,400 in patients in a study involving severe conditions resulting from SARS-CoV-2.
Iowa, an agricultural-intensive state with a population of 3.1 million reports about 1,270 cases alongside 29 deaths as of this writing. Local news reports that cities such as Des Moines are prepared for major economic hits from the pandemic.
Lead investigator Dr. Dilek Ince reports that the University of Iowa Hospitals & Clinics study team has been enrolling patients for about ten (10 days now and they report no major problems regarding drug side effects and that the team is working hard to do their best for patients afflicted with COVID-19 reports Rebecca David with KWQC-TV 6.
The investigator, a clinical associate professor of internal medicine in infectious diseases, leads the Iowa study effort and reports that they are using Remdesivir (Gilead). Dr. Ince noted the drug “is an infusion it is given through the IV. The trial is only for hospitalized patients because of this reason.”
Remdesivir, discovered by a collaborative team involving the University of Alabama, the National Institute of Allergy and Infectious Diseases and Gilead Sciences first was developed as a treatment for Ebola in human studies. The drug was also shown to be effective for MERS and SARS—both viruses in the same family as that of COVID-19.
University of Iowa Hospital & Clinics
University of Iowa and Clinics (UIHC) is an 811-bed public teaching hospital and level 1 trauma center affiliated with the University of Iowa. UI Hospitals and Clinics is part of University of Iowa Health Care, a partnership that includes the University of Iowa Roay J. and Lucille A. Carver College of Medicine and the University of Iowa Physicians Group practice. UI Hospitals and Clinics employs over 7,100 people and is overseen by the Iowa Board of Regents. It is a highly-comprehensive, tertiary-level center and also its premier medical facility.
University of Iowa Holden Comprehensive Cancer Center achieved National Cancer Institute (NCI) designation and hence is a hub of cancer-based research.
Dr. Dilek Ince, MD, Clinical Associate Professor of Internal Medicine – Infectious Diseases
Call to Action: If you know of someone afflicted with COVID-19 and hospitalized at University of Iowa, consider contacting the study team.